• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The CMO Market Outlook to 2017 Product Image

The CMO Market Outlook to 2017

  • Published: February 2012
  • Region: World
  • 119 Pages
  • Scripp Business Insights

FEATURED COMPANIES

  • Aenova
  • Catalent Pharma Solutions
  • DSM
  • Haupt
  • Lonza
  • Piramal
  • MORE

This report examines the markets for contract manufacturing of finished dose forms and clinical quantity pharmaceuticals. The report forecasts CMO markets for the US, Western Europe, Eastern Europe, China, India, Other Asia, Latin America and the rest of the world to 2017. Drivers and restraints for each regional market as well as the global market are also examined.

Features and benefits

- Develop contract manufacturing strategies based on regional forecast performance and key industry trends.

- Analyze the strengths and weaknesses of global players in the CMO market.

- Evaluate the future outlook of clinical quantity manufacturing as against finished dose supply.

- Assess the effects of CROs and big pharma drugmakers on the CMO market.

- Forecast CMO market sizes by region to 2017.

Highlights

In 2011, total global spending on outsourced drug manufacturing reached $31.9bn, having expanded at a double-digit pace over the past two decades. Over the next five years, the CMO industry will continue to record strong gains, with total revenues rising by 12.0% per year, on average.

In 2011, the US and Western Europe accounted for READ MORE >

About the author
- Disclaimer

EXECUTIVE SUMMARY
- The shifting drug manufacturing landscape
- The continued growth of contract manufacturing
- Continued demand in the established regions
- Strong growth in the emerging regions
- Leading global CMOs
- The future of contract manufacturing

The shifting drug manufacturing landscape
- Summary
- Introduction
- Rising pressures on drug makers
- Blockbuster patent expirations and genericization
- Decreasing drug approvals
- Drug pricing pressures
- Excess manufacturing capacity
- Technology shifts
- Biotechnology
- Conclusion

The continued growth of contract manufacturing
- Summary
- Contract manufacturing organizations
- The role of CMOs
- Services offered by CMOs
- CMO usage, 2012–2017
- Global CMO forecasts by segment
- Global CMO forecasts by world region
- Drivers of rising CMO usage
- Cost savings
- Risk reduction
- Shifting manufacturing requirements
- Lead time savings
- Access to expertise
- Expansion of overseas CMOs
- Entrance of Big Pharma into contract manufacturing
- Vertical integration with CROs
- Emergence of specialty CMO players
- Risk sharing programs
- Restraints inhibiting greater CMO usage
- Pharma industry consolidation
- Lack of specialized manufacturing capacity
- Manufacturing budget reductions
- Heightened regulatory scrutiny
- CMO personnel shortages
- CMO alternatives
- Conclusion

Continued demand in the established regions
- Summary
- Introduction
- The US CMO market
- Overview
- US CMO usage by segment, 2011–2017
- The Western European CRO market
- Overview
- Western European CMO usage by segment, 2011–2017
- Conclusion

Strong growth in the emerging regions
- Summary
- Introduction
- The Eastern European CMO market
- Overview
- The Chinese CMO market
- Overview
- Chinese CMO usage by segment, 2011–2017
- The Indian CMO market
- Overview
- Indian CMO usage by segment, 2011–2017
- The Asian CMO market, exclusive of China and India
- Overview
- Other Asian CMO usage by segment, 2011–2017
- The Latin American CRO market
- Overview
- Latin American CMO usage by segment, 2011–2017
- Conclusion

Leading global CMOs
- Summary
- Introduction
- Leading Players
- Aenova
- Boehringer Ingelheim
- Catalent Pharma Solutions
- Dr. Reddy’s
- DSM
- Fareva
- Haupt
- Jubilant Organosys
- Lonza
- Patheon
- Piramal
- Tianjin Pharmaceutical
- Conclusion

The future of contract manufacturing
- Summary
- Introduction
- The drug manufacturing landscape in the US and EU
- Near term: 2012–2013
- Long term: 2014–2017
- Manufacturing outsourcing trends
- Near term: 2012–2013
- Long term: 2014–2017
- Conclusion

Appendix
- Scope
- Methodology
- Primary research
- Secondary research
- Glossary/Abbreviations
- Bibliography/References

FIGURES
- Figure: Usage of clinical and final dosage CMO services by type of drug maker
- Figure: Global CMO market by segment ($bn), 2012–17
- Figure: CMO market by region ($bn)
- Figure: CMO fees in the established regions ($bn), 2011–17
- Figure: US CMO fees by segment ($bn), 2011–17
- Figure: US CMO market players by market share, 2011
- Figure: Western European CMO fees by segment ($bn), 2011–17
- Figure: Western European CMO market players by market share, 2011
- Figure: Eastern European CMO fees by segment ($bn), 2011–17
- Figure: Eastern European CMO market players by market share, 2011
- Figure: Chinese CMO fees by segment ($bn), 2011–17
- Figure: Chinese CMO market players by market share, 2011
- Figure: Indian CMO fees by segment ($bn), 2011–17
- Figure: Indian CMO market players by market share, 2011
- Figure: Other Asian CMO fees by segment ($bn), 2011–17
- Figure: Leading Other Asian CMO market players, 2011
- Figure: Latin American CMO fees by segment ($bn), 2011–17
- Figure: Leading Latin American CMO market players, 2011
- Figure: Forces driving and restraining CMO growth in the near and long term

- Aenova
- Boehringer Ingelheim
- Catalent Pharma Solutions
- Dr. Reddy’s
- DSM
- Fareva
- Haupt
- Jubilant Organosys
- Lonza
- Patheon
- Piramal
- Tianjin Pharmaceutical

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos